Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - Cantor Fitzgerald has reiterated an Overweight rating and $26.00 price target on AxoGen, Inc. (NASDAQ:AXGN) following the company’s second-quarter 2025 financial results. According to InvestingPro data, analyst targets for the stock range from $20 to $30, with the company maintaining a "Good" financial health score.
AxoGen reported revenue of $56.7 million for the quarter, exceeding both Cantor Fitzgerald’s estimate of $50.2 million and the FactSet consensus of $53.0 million. This represents year-over-year growth of approximately 18.3%, driven by double-digit growth across the company’s product portfolio. The company maintains an impressive gross margin of 74.27% and has demonstrated consistent growth with a five-year revenue CAGR of 12%.
The company reported having 641 active high-potential accounts in the first half of 2025, showing year-over-year growth of approximately 3%. Following these results, AxoGen increased its revenue guidance for calendar year 2025.
During the quarter, AxoGen completed several regulatory milestones, including a late-cycle meeting with the FDA, a pre-licensing inspection, and a sponsor inspection under the FDA’s Bioresearch Monitoring Program. These steps support the company’s Biologics License Application (BLA) ahead of its September 5 PDUFA date.
BLA approval would secure 12 years of market exclusivity from biosimilar nerve allografts and establish AxoGen’s Avance as the only implantable biologic indicated for the repair of functional deficits in peripheral nerves.
In other recent news, AxoGen Inc. reported impressive financial results for the second quarter of 2025, surpassing both earnings and revenue projections. The company announced an adjusted earnings per share of $0.12, which is double the expected $0.06, and a revenue of $56.7 million, exceeding the forecast of $52.66 million. This strong performance has caught the attention of analysts. Jefferies raised its price target for AxoGen to $25 from $24, maintaining a Buy rating due to robust sales growth that outpaced consensus estimates by approximately 8%. Meanwhile, Raymond (NSE:RYMD) James lowered its price target to $20 from $21 but kept an Outperform rating, noting improved momentum in revenue growth and gross margin performance. These developments indicate positive momentum for AxoGen as it continues to show strong market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.